Citro Vincenzo, Fristachi Raffaele, Tarantino Giovanni
Department of Clinical and Experimental Medicine, Federico II University Medical School of Naples, Italy.
J Med Case Rep. 2007 Sep 17;1:86. doi: 10.1186/1752-1947-1-86.
This paper describes the clinical course of a patient with chronic hepatitis C, genotype 2a/2c, previously treated with Interferon alpha2b and subsequently with Lymphoblastoid Interferon without any response, and also without any cutaneous side effects. The patient, a 50 year-old woman, was re-treated with Pegylated alpha2b Interferon plus Ribavirin for 24 weeks, at standard doses; during the third month of therapy she developed a mild form of psoriasis. However, encouraged by the progressive improvement of her transaminase levels and viral load decrease, the patient asked to continue the treatment; she normalized the transaminase levels during the fourth month and showed HCV-RNA negativity during the fifth month of therapy. Nevertheless, the psoriasis become worse, extending to over 75% of her body. Therapy was completed after sixth months. A month after the therapy was ceased, the patient's psoriasis receded spontaneously and completely. During the subsequent four years the patient did not experience any recurrence of either the hepatic disease or the psoriasis.
本文描述了一名慢性丙型肝炎患者的临床病程，该患者为2a/2c基因型，曾接受α2b干扰素治疗，随后接受淋巴母细胞干扰素治疗，但均无反应，且无任何皮肤副作用。该患者为一名50岁女性，接受聚乙二醇化α2b干扰素联合利巴韦林标准剂量治疗24周；治疗第三个月时，她出现了轻度银屑病。然而，由于转氨酶水平逐渐改善和病毒载量下降，患者要求继续治疗；她在第四个月时转氨酶水平恢复正常，在治疗第五个月时HCV-RNA呈阴性。尽管如此，银屑病病情加重，蔓延至身体超过75%的部位。六个月后治疗结束。治疗停止一个月后，患者的银屑病自发且完全消退。在随后的四年里，患者的肝病和银屑病均未复发。
